The stock escaped the broader selloff of March 2020 and remained unfazed in the face of the Covid 2.0 volatility, as it kept on hitting record highs every now and then.
The drug maker s consolidated net profit soared 170% to Rs 297 crore on 68% surge in net sales to Rs 1,412 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, EBITDA grew 147% to Rs 477 crore in Q4 FY21 over Q4 FY20 while EBITDA margins stood at 34%. The board approved an interim dividend amounting to Re 0.80 per share.
The net profit soared 286% to Rs 984 crore on 70% surge in net sales to Rs 4,814 crore in the year ended March 2021 (FY21) over the year ended March 2020 (FY20). EBITDA grew 176% to Rs 1,573 crore in FY21 over FY20 while EBITDA margins stood at 33%.
The Reaseach and Development (R&D) expense stood at Rs 184 crore in FY21 which is 4% of its sales in FY21. The Generic FDF segment recorded a sale of Rs 430 crore, which is 30% of the contribution in Q4 and Rs 1,664 crore, 35% contribution in FY21.
Laurus Labs Ltd posts Q4FY21 consolidated PAT higher at Rs 296 68 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.